Airway Therapeutics, Inc.
Publicly observedAtlanta, United States
Seen in a public record (e.g. a government grant database); not otherwise verified.
Details and provenance
| Item | Value | Source | Status |
|---|---|---|---|
| Country | US | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| City / locality | Atlanta | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| Name | Airway Therapeutics, Inc. | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| UEI (U.S. federal entity ID) | KXA4TU327G25 | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
Recorded events
- Grant10 Sept 2026Publicly observed
NIH SBIR/STTR award: A Randomized,Phase 2b/3 Study to Evaluate the Efficacy and Safety of Zelpultide Alfa in Preventing BPD in High-Risk Preterm Neonates Compared to Standard of Care.
USD 1,906,253.00 · National Heart Lung and Blood Institute · Source: NIH RePORTER (opens in a new tab)
Information only — not investment advice or an endorsement. Is this your company? Submit or update its details or request a correction.